Heparin Sodium Wockhardt Uk (Heparin Sodium)

Heparin Sodium Wockhardt Uk is employed in clinical practice for several antithrombotic indications where rapid anticoagulation is required.

• Prevention of venous thromboembolism (VTE) in patients undergoing major surgery or immobilization.
• Treatment of acute deep‑vein thrombosis (DVT) to limit clot extension.
• Management of pulmonary embolism (PE) as part of an initial anticoagulant regimen.
• Prophylaxis of clot formation during cardiac or vascular procedures that involve extracorporeal circulation.
• Use in heparin‑induced thrombocytopenia (HIT) testing protocols as a reference anticoagulant.

Adverse reactions to Heparin Sodium Wockhardt Uk are reported across a range of frequencies and may involve hematologic, allergic, or systemic manifestations.

Common

• Minor bleeding at the injection site or bruising.
• Transient elevation of liver enzymes without clinical symptoms.
• Mild thrombocytopenia that resolves with continued therapy.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.

When prescribing Heparin Sodium Wockhardt Uk, clinicians should observe several precautionary measures to minimize risk and ensure safe use.

• Assess baseline coagulation parameters and platelet count before initiation.
• Adjust dose in patients with renal or hepatic impairment, as drug clearance may be altered.
• Monitor activated partial thromboplastin time (aPTT) regularly to maintain therapeutic range.
• Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products.
• Consider alternative anticoagulation in pregnant patients unless benefits outweigh potential risks.
• Discontinue promptly if signs of HIT or uncontrolled bleeding develop.

Heparin Sodium Wockhardt Uk can interact with other medicines that affect hemostasis or share metabolic pathways, requiring careful management.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) that may amplify bleeding risk.
• Administration of thrombolytic agents such as alteplase or streptokinase, which can lead to severe hemorrhage.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and antiplatelet agents (e.g., aspirin, clopidogrel) may increase minor bleeding.
• High‑dose corticosteroids can potentiate anticoagulant effect.
• Certain antibiotics (e.g., quinolones) have been associated with platelet dysfunction when combined with heparin.